• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Longer duration of elastic compression therapy may help prevent post-thrombotic syndrome

byDeepti ShroffandDavid Wang
July 24, 2016
in Chronic Disease
Reading Time: 2 mins read
Longer duration of elastic compression therapy may help prevent post-thrombotic syndrome
Share on FacebookShare on Twitter

1. In a randomized controlled trial of over 500 patients with a diagnosis of deep vein thrombosis (DVT), the use of elastic compression therapy (ECT) for 1 year was inferior to use of ECT for 2 years.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Post-thrombotic syndrome is a complication of DVT, characterized by leg swelling, pain, and skin ulcerations, which can cause significant impairment in quality of life. Previous studies have demonstrated that the use of ECT for 2 years after DCT significantly reduces the occurrence of post-thrombotic syndrome after DVT. However, compliance to ECT has been a challenge due to local irritation and cosmetic reasons. The purpose of this study was to determine whether a shorter duration of ECT is inferior to the standard two-year therapy.

The trial randomized over 500 patients with a diagnosis of DVT to either 1- or 2-year duration of ECT treatment. The main outcome was the incidence of post-thrombotic syndrome at 24 months. At the conclusion of the trial, a 1-year duration of ECT was not non-inferior to completing a 2-year duration of ECT. The patients in the 1-year ECT group was associated with a significantly increased number of post-thrombotic syndrome within the second year. The results of this study demonstrate that strong adherence to ECT may affect the natural history of post-thrombotic syndrome. The study is strengthened by the large sample size and multi-center design. However, only patients with high compliance to ECT were included in the study, which may limit the external generalizability of the results.

Click to read the study in BMJ

Relevant Reading: The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial

RELATED REPORTS

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

In-Depth [randomized controlled trial]: This was a single-blind, multi-center randomized controlled trial of 1- versus 2-year ECT therapy in the prevention of post-thrombotic syndrome. Overall, 518 patients from eight centers in the Netherlands were recruited between 2009 to 2013. The primary outcome measured was the occurrence of post-thrombotic syndrome two years after DVT diagnosis. At the conclusion of the trial, the incidence of post-thrombotic syndrome for the one-year ECT duration group was 19.9% (95%CI: 16%-24%). In the 2-year ECT group, the incidence of post-thrombotic syndrome at 24 months was 13% (95%CI: 9.9% to 17%). As such, non-inferiority could not be reached between the two groups. Overall, the number needed to treat one case of post-thrombotic syndrome by the continued use of ECT was 14.

Image: CC/Wiki/Patho

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: deep vein thrombosis (DVT)elastic compression therapy (ECT)hematology
Previous Post

All glucose-lowering medications effective, but some offer lower hypoglycemia risks

Next Post

Participation in sports and exercise linked to lower opioid use

RelatedReports

Combined lenalidomide and rituximab dose escalation found to be safe for CLL
All Specialties

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

June 8, 2026
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Cardiology

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

April 9, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Variation noted across pre- and post-marketing studies for FDA approved devices
Hematology

FDA grants priority review for iberdomide-based myeloma regimen

March 6, 2026
Next Post
Participation in sports and exercise linked to lower opioid use

Participation in sports and exercise linked to lower opioid use

Rehabilitation after immobilization for ankle fracture: The EXACT trial

2 Minute Medicine Rewind July 25, 2016

Normal renal ultrasound only rules out high grade vesicoureteral reflux in infants

Delayed antimicrobial therapy in pediatric febrile UTI associated with renal scarring

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Nirsevimab (Beyfortus) may reduce severe respiratory syncytial virus infections among infants
  • An artificial intelligence (AI) tool achieved high diagnostic accuracy for the identification and prediction of sepsis
  • Use of long-acting broadly neutralizing antibodies may delay human immunodeficiency virus (HIV) rebound following discontinuation of antiretroviral therapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.